Palvella Therapeutics files Rule 144 for 05/20/2026 sale

Palvella Therapeutics filed a Rule 144 notice reporting the proposed sale of Common Stock on 05/20/2026 associated with a stock option exercise to the issuer for cash.

Rhea-AI Filing Summary

Palvella Therapeutics filed a Rule 144 notice reporting the proposed sale of Common Stock on 05/20/2026 associated with a stock option exercise to the issuer for cash. The filing lists broker details and transaction references including $475,630.84 and an aggregate figure 14,342,844 alongside prior sale entries by Kathleen Goin on 03/18/2026 and 04/15/2026 with amounts $507,611.05 and $547,398.96.

Insights

Securities Compliance Attorney

Rule 144 notice records an issuer-directed option exercise and cash-based sale planned for 05/20/2026.

The filing identifies a stock option exercise method and shows the sale is to the issuer for cash. It also lists broker information and monetary figures $475,630.84 and 14,342,844 as referenced in the schedule.

Prior dispositions by Kathleen Goin on 03/18/2026 and 04/15/2026 are recorded with amounts $507,611.05 and $547,398.96; filings like this are routine transfer notices under resale restrictions.

Key Figures

Planned sale date: 05/20/2026 Referenced amount: $475,630.84 Referenced aggregate figure: 14,342,844 +3 more

6 metrics

Planned sale date 05/20/2026 Scheduled date for the stock option exercise and sale

Referenced amount $475,630.84 Amount shown in the security information section

Referenced aggregate figure 14,342,844 Numeric aggregate number listed in the filing excerpt

Prior sale - 03/18/2026 $507,611.05 Disposition by Kathleen Goin recorded in the form

Prior sale - 04/15/2026 $547,398.96 Disposition by Kathleen Goin recorded in the form

Broker listed Piper Sandler & Co Broker-dealer named in the securities section

Key Terms

Rule 144, Stock Option Exercise, Issuer

3 terms

Rule 144 regulatory

"Filed a Rule 144 notice reporting the proposed sale of Common Stock"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Stock Option Exercise financial

"Listed as the method: Stock Option Exercise to Issuer for Cash"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

Issuer financial

"Securities To Be Sold — Stock Option Exercise — Issuer — Cash"

FAQ

What does Palvella Therapeutics' Form 144 (PVLA) report on 05/20/2026?

It reports a proposed sale of Common Stock on 05/20/2026 tied to a stock option exercise with proceeds to the issuer. The filing lists transaction method as cash and broker contact details.

Who appears as a recent seller in the Form 144 filing for PVLA?

The filing lists Kathleen Goin with recorded dispositions on 03/18/2026 and 04/15/2026, showing amounts of $507,611.05 and $547,398.96 respectively.

What transaction method is specified in the PVLA Form 144?

The filing specifies a Stock Option Exercise with the sale labeled as to the issuer and the consideration as cash, per the form entries for 05/20/2026.

Does the Form 144 show broker or intermediary details for PVLA?

Yes; the filing includes broker information naming Piper Sandler & Co with an address and an exchange listing of Nasdaq in the security details.

Are prior three‑month sales disclosed in the PVLA Form 144?

Yes; the form records prior sales during the past three months by Kathleen Goin on 03/18/2026 and 04/15/2026 with amounts $507,611.05 and $547,398.96.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/20/2026 - 05:47 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001912570
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	PALVELLA THERAPEUTICS, INC.
SEC File Number	001-37471
Address of Issuer	353 W. LANCASTER AVENUE SUITE 200 WAYNE PENNSYLVANIA 19087
Phone	(484) 253-1461
Name of Person for Whose Account the Securities are To Be Sold	Goin Kathleen
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Piper Sandler & Co Inc 350 N 5th St Ste 1000 Minneapolis MN 55401	4302	475630.84	14342844	05/20/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	05/20/2026	Stock Option Exercise	Issuer			4302	05/20/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Kathleen Goin C/O Palvella Therapeutics Inc 353 W Lancaster Ave Ste 200 Wayne PA 19087	Common Stock	03/18/2026	4302	507611.05
Kathleen Goin C/O Palvella Therapeutics Inc 353 W Lancaster Ave Ste 200 Wayne PA 19087	Common Stock	04/15/2026	4302	547398.96

144: Remarks and Signature

Remarks
Date of Notice	05/20/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/19/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Alex Johnson, a duly authorized representative of Piper Sandler & Co Corporate & Venture Services FA, as attorney-in-fact for Kathleen Goin
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)